📊 NUMD Key Takeaways
Is Nu-Med Plus, Inc. (NUMD) a Good Investment?
Nu-Med Plus is in severe financial distress with negative stockholders' equity of -$215.1K, indicating the company is technically insolvent. Revenue has collapsed 400% YoY to negative territory while operating losses continue to mount, demonstrating fundamental business failure. The company has minimal cash reserves of $2.4K against $224.5K in liabilities and negative operating cash flow, indicating imminent insolvency without significant capital infusion.
Nu-Med Plus exhibits essentially no revenue, persistent losses, and acute balance-sheet stress with negative equity and minimal cash. Reported margins are distorted by negative revenue, while ROA and interest coverage point to insolvency risk. Without a near-term capital raise and tangible, recurring revenue traction, the fundamentals remain untenable.
Nu-Med Plus, Inc. Key Strengths (NUMD)
- Minimal capital expenditure requirements reduce cash burn in operations
- Zero long-term debt structure limits refinancing risk
- Severely distressed valuation may offer distressed asset recovery opportunity for turnaround specialists
- Asset-light model with zero capex requirements
- Net loss improved YoY, suggesting some cost control
- No long-term debt recorded, limiting fixed obligations
NUMD Stock Risks: Nu-Med Plus, Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency and heightened bankruptcy risk
- Revenue collapse of 400% YoY demonstrates total loss of business viability
- Critical liquidity crisis with current ratio of 0.04x and only $2.4K cash against $224.5K liabilities
- Negative operating cash flow of -$4.4K indicates operational losses are not self-sustaining
- Complete absence of profitability with net income loss of $68.3K in latest period
- No insider buying activity in past 90 days suggests management confidence is absent
- Going-concern risk given negative equity, 0.04x current ratio, and minimal cash
- High dilution risk from likely capital raises to fund operations
- Execution risk in returning to positive, sustainable revenue
Key Metrics to Watch
- Stockholders equity trend - any improvement from negative -$215.1K position
- Monthly revenue stabilization - current negative revenue is unsustainable
- Cash burn rate and runway until complete depletion of $2.4K reserves
- Debt covenant compliance and default risk
- Asset liquidation values and going concern assessment
- Cash & Equivalents
- Revenue (return to positive, growth rate)
Nu-Med Plus, Inc. (NUMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 88.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
NUMD Profit Margin, ROE & Profitability Analysis
NUMD vs Healthcare Sector: How Nu-Med Plus, Inc. Compares
How Nu-Med Plus, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nu-Med Plus, Inc. Stock Overvalued? NUMD Valuation Analysis 2026
Based on fundamental analysis, Nu-Med Plus, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nu-Med Plus, Inc. Balance Sheet: NUMD Debt, Cash & Liquidity
NUMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nu-Med Plus, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
NUMD Revenue Growth, EPS Growth & YoY Performance
NUMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$15.9K | $0.00 |
| Q1 2021 | N/A | -$153.3K | N/A |
| Q3 2020 | N/A | -$150.6K | N/A |
| Q2 2020 | N/A | -$153.3K | N/A |
| Q1 2020 | N/A | -$153.3K | $0.00 |
| Q3 2019 | N/A | -$147.5K | N/A |
| Q2 2019 | N/A | -$147.5K | N/A |
| Q1 2019 | N/A | -$147.5K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nu-Med Plus, Inc. Dividends, Buybacks & Capital Allocation
NUMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nu-Med Plus, Inc. (CIK: 0001543637)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUMD
What is the AI rating for NUMD?
Nu-Med Plus, Inc. (NUMD) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUMD's key strengths?
Claude: Minimal capital expenditure requirements reduce cash burn in operations. Zero long-term debt structure limits refinancing risk. ChatGPT: Asset-light model with zero capex requirements. Net loss improved YoY, suggesting some cost control.
What are the risks of investing in NUMD?
Claude: Negative stockholders' equity indicates technical insolvency and heightened bankruptcy risk. Revenue collapse of 400% YoY demonstrates total loss of business viability. ChatGPT: Going-concern risk given negative equity, 0.04x current ratio, and minimal cash. High dilution risk from likely capital raises to fund operations.
What is NUMD's revenue and growth?
Nu-Med Plus, Inc. reported revenue of $-5.0K.
Does NUMD pay dividends?
Nu-Med Plus, Inc. does not currently pay dividends.
Where can I find NUMD SEC filings?
Official SEC filings for Nu-Med Plus, Inc. (CIK: 0001543637) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUMD's EPS?
Nu-Med Plus, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NUMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Nu-Med Plus, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NUMD stock overvalued or undervalued?
Valuation metrics for NUMD: ROE of N/A (sector avg: 15%), net margin of 1,366.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NUMD's AI grade for 2026?
Our dual AI analysis gives Nu-Med Plus, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NUMD's free cash flow?
Nu-Med Plus, Inc.'s operating cash flow is $-4.4K, with capital expenditures of $0.0. FCF margin is 88.7%.
How does NUMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,366.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.04 (avg: 2).